共 35 条
- [31] Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (09) : 2742 - 2751
- [32] Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) : 3698 - 3699
- [33] Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-Infected individuals receiving long-term highly active antiretroviral therapy JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (11): : 1672 - 1676
- [34] Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (12) : 3699 - 3700
- [35] Continued Low Rates of Hepatitis C Virus (HCV) Recurrence in HCV/HIV- and HCV-Infected Participants Who Achieved Sustained Virologic Response After Direct-Acting Antiviral Treatment: Final Results From the AIDS Clinical Trials Group A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (12):